7 January 2015

Professor Andrew Pollard
Chair, Joint Committee on Vaccination and Immunisation
Public Health England
Wellington House
133-155 Waterloo Road
London SE1 8UG

By email

Dear Professor Pollard

JCVI interim position statement on HPV vaccination of men who have sex with men (MSM)

BHIVA welcomes this report and strongly supports a recommendation to offer quadrivalent HPV vaccination to all MSM aged 16-40.

BHIVA believes the following issues should also be considered:

1. In the absence of universal vaccination of adolescent males and in view of vaccine efficacy being greatest in those who are not yet sexually active, we believe boys aged 12-16 who self-declare that they are sexually attracted to other males should be eligible for vaccination. A recommendation to commence vaccination at 16 years is discriminatory.

2. HPV vaccination of HIV positive men should take place in HIV clinics. The different commissioning arrangements required for this should be considered.

3. In view of the disproportionate burden of HPV related cancer in all people living with HIV, we believe assessment of the cost-effectiveness of catch-up vaccination in heterosexual, HIV-positive men and women up to age 40 should be undertaken.

4. Publishing the PHE/UCL report in full should be considered.

With kind regards

Yours sincerely

Dr David Asboe
Chair, British HIV Association (BHIVA)